M
MEDx Translational
Precision medicine solutions for clinical drug development
About MEDx Translational
MEDx Translational Medicine, formerly known as QIAGEN (Suzhou) Translational Medicine Co., Ltd., was established in 2013 and operates as a provider of companion diagnostics and translational medicine solutions for precision medicine in China. The company provides integrated solutions that cover biomarker discovery, target validation, molecular testing, and patient stratification to support drug clinical trials and the research, development, and commercialization of in-vitro diagnostics (IVD) and companion diagnostics (CDx).
MEDx utilizes comprehensive translational platforms, including genomics, proteomics, cytomics, and pathology, to serve its clients. The firm offers diagnostic solutions for solid tumors and hematological malignancies through assays based on immunohistochemistry (IHC), polymerase chain reaction (PCR), and next-generation sequencing (NGS) technologies. The company collaborates with pharmaceutical companies to advance precision medicine. In 2021, MEDx extended a strategic partnership with Abcam to co-develop and commercialize companion and in-vitro diagnostic kits for the Chinese market. The company is also a founding member of the China Precision Medicine and Companion Diagnosis Committee, part of the Chinese Society of Biotechnology.
The company's history includes a joint venture with QIAGEN N.V. in 2013 and securing strategic investors such as Simcere Pharma and Shanghai Anjie Medical Equipment Co., Ltd. It has received multiple certifications, including China CNAS, ISO17025, CAP accreditation, and ISO 13485.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Suzhou Shi, China
- Open positions
- None listed
- Dealroom signal
- 22.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Oct 2020 | $51M | $206M | Qiming Venture Partners · Tsing Capital · Sinopharm Capital · Quan Capital | — |
Growth signals
Latest recorded traffic for MEDx Translational is 280 monthly website visits, down 76.7% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Qiming Venture Partners- TCTsing Capital
- SCSinopharm Capital
Quan Capital
Broad Resources
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about MEDx Translational on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MEDx Translational’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.